The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect?
Open accessAbstract
Coronavirus disease 2019 (COVID-19) arose at a time of great concern about antimicrobial resistance (AMR). No studies have specifically assessed COVID-19–associated superinfections or AMR. Based on limited data from case series, it is reasonable to anticipate that an appreciable minority of patients with severe COVID-19 will develop superinfections, most commonly pneumonia due to nosocomial bacteria and Aspergillus. Microbiology and AMR patterns are likely to reflect institutional ecology. Broad-spectrum antimicrobial use is likely to be widespread among hospitalized patients, both as directed and empiric therapy. Stewardship will have a crucial role in limiting unnecessary antimicrobial use and AMR. Congressional COVID-19 relief bills are considering antimicrobial reimbursement reforms and antimicrobial subscription models, but it is unclear if these will be included in final legislation. Prospective studies on COVID-19 superinfections are needed, data from which can inform rational antimicrobial treatment and stewardship strategies, and models for market reform and sustainable drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263 · cited 6×
“In a report from 552 hospitals in 30 Chinese provinces, 58% of patients were treated with antibiotics [17].”
BackgroundInfluentialChen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study
Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., et al. (2020) · BMJ · doi:10.1136/bmj.m1091 · Cited by 3,903 · cited 7×
“D ow nloaded from https://academ ic.oup.com /cid/advance-article-abstract/doi/10.1093/cid/ciaa524/5828436 by guest on 09 M ay 2020 D ow Ac ce pt ed M an us cr ipt characterized Chen T2 [14] Wuhan, 1 hospital 2743 Hospitalized 43% Abx, 91% 79% N/S N/S N/S Cao [13] Wuhan, 1 hospital 102 Hospitalized 18% in ICU 14% Abx,…”
BackgroundInfluential(2016) · Cited by 2,888
Covid-19 in Critically Ill Patients in the Seattle Region — Case Series
Bhatraju, P. K., Ghassemieh, B. J., Nichols, M., Kim, R., Jerome, K. R., Nalla, A. K., Greninger, A. L., Pipavath, S., Wurfel, M. M., Evans, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004500 · Cited by 2,583
Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State
Arentz, M., Yim, E., Klaff, L., Lokhandwala, S., Riedo, F. X., Chong, M., & Lee, M. (2020) · JAMA · doi:10.1001/jama.2020.4326 · Cited by 2,259
Clinical Characteristics of Covid-19 in New York City
Goyal, P., Choi, J. J., Pinheiro, L. C., Schenck, E. J., Chen, R., Jabri, A., Satlin, M. J., Campion, T. R., Nahid, M., Ringel, J. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2010419 · Cited by 2,234
Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2008) · The Journal of Infectious Diseases · doi:10.1086/591708 · Cited by 1,625 · cited 1×
“During 1918 and subsequent influenza pandemics, Streptococcus pneumoniae and other bacterial superinfections were common causes of mortality and morbidity.[3] Recent retrospective studies have suggested that aspergillosis and other fungal infections are under-recognized complications of severe influenza.”
BackgroundPedersen, S. F., & Ho, Y.-C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137647 · Cited by 1,137 · cited 2×
“, interleukin-4, interleukin-10) levels, fewer CD4 and CD8 cells, and less interferon-gamma expression by CD4 cells than those with more moderate disease, which likely contributes to lung pathology.[32, 33] Cytokine release syndrome, immune exhaustion”
BackgroundClinical and virological data of the first cases of COVID-19 in Europe: a case series
Lescure, F.-X., Bouadma, L., Nguyen, D., Parisey, M., Wicky, P.-H., Behillil, S., Gaymard, A., Bouscambert-Duchamp, M., Donati, F., Le Hingrat, Q., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30200-0 · Cited by 1,092
Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China
Wang, Z., Yang, B., Li, Q., Wen, L., & Zhang, R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa272 · Cited by 1,063
Chen, X., Zhao, B., Qu, Y., Chen, Y., Xiong, J., Feng, Y., Men, D., Huang, Q., Liu, Y., Yang, B., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa449 · Cited by 1,020
Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study
Du, Y., Tu, L., Zhu, P., Mu, M., Wang, R., Yang, P., Wang, X., Hu, C., Ping, R., Hu, P., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0543oc · Cited by 942
Schauwvlieghe, A. F. A. D., Rijnders, B. J. A., Philips, N., Verwijs, R., Vanderbeke, L., Van Tienen, C., Lagrou, K., Verweij, P. E., Van de Veerdonk, F. L., Gommers, D., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30274-1 · Cited by 886
Trends in antimicrobial drug development: Implications for the future
Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867
Preparing for the Next Pandemic
Osterholm, M. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058068 · Cited by 651
Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017.
Jernigan, J. A., Hatfield, K. M., Wolford, H., Nelson, R. E., Olubajo, B., Reddy, S. C., McCarthy, N., Paul, P., McDonald, L. C., Kallen, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914433 · Cited by 577
Cao, J., Tu, W.-J., Cheng, W., Yu, L., Liu, Y.-K., Hu, X., & Liu, Q. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa243 · Cited by 495
Aspergillus fumigatus morphology and dynamic host interactions
van de Veerdonk, F. L., Gresnigt, M. S., Romani, L., Netea, M. G., & Latgé, J.-P. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.90 · Cited by 490 · cited 1×
“[3] Recent retrospective studies have suggested that aspergillosis and other fungal infections are under-recognized complications of severe influenza.[4, 5] The extent to which COVID-19 is complicated by”
BackgroundCritical analysis of antibacterial agents in clinical development
Theuretzbacher, U., Bush, K., Harbarth, S., Paul, M., Rex, J. H., Tacconelli, E., & Thwaites, G. E. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0340-0 · Cited by 373
Eleven faces of coronavirus disease 2019
Dong, X., Cao, Y., Lu, X., Zhang, J., Du, H., Yan, Y., Akdis, C. A., & Gao, Y. (2020) · Allergy · doi:10.1111/all.14289 · Cited by 347
Lian, J., Jin, X., Hao, S., Cai, H., Zhang, S., Zheng, L., Jia, H., Hu, J., Gao, J., Zhang, Y., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa242 · Cited by 340
Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia
Hsu, L.-Y., Apisarnthanarak, A., Khan, E., Suwantarat, N., Ghafur, A., & Tambyah, P. A. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-16 · Cited by 339
Talbot, G. H., Jezek, A., Murray, B. E., Jones, R. N., Ebright, R. H., Nau, G. J., Rodvold, K. A., Newland, J. G., Boucher, H. W., & The Infectious Diseases Society of America (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz089 · Cited by 168
Clancy, C. J., Potoski, B. A., Buehrle, D. J., & Nguyen, M. H. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz344 · Cited by 67
Self-citationÅrdal, C., Røttingen, J., Opalska, A., van Hengel, A. J., & Larsen, J. C. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix526 · Cited by 40
Combating Resistance While Maintaining Innovation: The Future of Antimicrobial Stewardship
Vickers, R. J., Bassetti, M., Clancy, C. J., Garey, K. W., Greenberg, D. E., Nguyen, M.-H., Roblin, D., Tillotson, G., & Wilcox, M. H. (2019) · Future Microbiology · doi:10.2217/fmb-2019-0227 · Cited by 26
Self-citationClancy, C. J., & Nguyen, M. H. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-19 · Cited by 26
Self-citation
Cited by
Langford, B. J., So, M., Raybardhan, S., Leung, V., Westwood, D., MacFadden, D. R., Soucy, J.-P. R., & Daneman, N. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.07.016 · Cited by 1,569
Vaughn, V. M., Gandhi, T. N., Petty, L. A., Patel, P. K., Prescott, H. C., Malani, A. N., Ratz, D., McLaughlin, E., Chopra, V., & Flanders, S. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1239 · Cited by 396
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
Ripa, M., Galli, L., Poli, A., Oltolini, C., Spagnuolo, V., Mastrangelo, A., Muccini, C., Monti, G., De Luca, G., Landoni, G., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.10.021 · Cited by 363
Antimicrobial resistance and COVID-19: Intersections and implications
Knight, G. M., Glover, R. E., McQuaid, C. F., Olaru, I. D., Gallandat, K., Leclerc, Q. J., Fuller, N. M., Willcocks, S. J., Hasan, R., van Kleef, E., et al. (2021) · eLife · doi:10.7554/elife.64139 · Cited by 355
Nori, P., Cowman, K., Chen, V., Bartash, R., Szymczak, W., Madaline, T., Punjabi Katiyar, C., Jain, R., Aldrich, M., Weston, G., et al. (2021) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2020.368 · Cited by 290
Metadata
- Authors
- Clancy, C. J., & Nguyen, M. H.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-05-01
- Volume
- 71
- Issue
- 10
- Pages
- 2736-2743
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3021567865
- Cited by
- 274
- References
- 36
- FWCI
- 32.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.